SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Champignon Brands Inc. - SHRMF

Pomerantz LLP is investigating claims on behalf of investors of Champignon Brands Inc. ("Champignon" or the "Company") (OTCMKTS: SHRMF). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether Champignon and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On February 17, 2021 , Champignon announced that "the Company has determined to withdraw and refile its condensed interim consolidated financial statements and management's discussion & analysis ('MD&A') for the three and six month periods ended March 31, 2020 ". The Company advised investors that "[f]or the three and six month periods ended March 31, 2020 , the Company previously recognized intangible assets in connection with the acquisitions of Artisan Growers Ltd., Novo Formulations Ltd. and Tassili Life Sciences Corp. (the 'Acquisitions') that aggregated approximately $12 million ," but that subsequently "management determined that the financial statements needed to be restated to correct the accounting for the Acquisitions as the assets do not meet the definition of intangible assets for the purposes of international financial reporting standards and as result will be recorded as transaction costs in the Company's statement of loss and comprehensive loss."  The Company also announced that "it was determined that a shareholder and contracted consultant (the 'Consultant') of the Company was a related party with respect to the Acquisitions."

On this news, Champignon's stock price fell roughly $0.08 per share, or 10.78% to close at $0.69 per share on February 17, 2021 .

The Pomerantz Firm, with offices in New York , Chicago , Los Angeles , and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

Cision View original content: https://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-champignon-brands-inc---shrmf-301249781.html

SOURCE Pomerantz LLP

News Provided by PR Newswire via QuoteMedia

The Conversation (0)
Lobe Sciences Reports First Quarter 2026 Results and Highlights

Lobe Sciences Reports First Quarter 2026 Results and Highlights

VANCOUVER, BC / ACCESS Newswire / February 3, 2026 / lobe sciences ltd. (CSE:LOBE,OTC:LOBEF)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported unaudited financial results for the first... Keep Reading...
Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors

Lobe Sciences Advances Governance and Capital Markets Expertise with Appointment of Mr. Nick Karakochuk to the Board of Directors

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 13, 2026 / lobe sciences ltd. ("Lobe Sciences" or the "Company") (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F), a clinical-stage biopharmaceutical company focused on advancing therapies for diseases with significant unmet medical needs, today... Keep Reading...
Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

Lobe Sciences Reports FY2025 with a Stronger Balance Sheet and Sharpened Strategy

Balance Sheet and Sharpened Strategy VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 8, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(Frankfurt:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported... Keep Reading...
Solvonis Therapeutics

U.S. Patent allowance received for PTSD discovery programme

Solvonis Therapeutics plc (LSE: SVNS), an emerging biopharmaceutical company developing novel medicines for high-burden central nervous system ("CNS") disorders, announces that it has received a Notice of Allowance (the "Allowance") from the United States Patent and Trademark Office ("USPTO")... Keep Reading...
Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

Lobe Sciences Reports Fiscal 2025 Results and Highlights Strategic Transformation Following Leadership Transition

VANCOUVER, BRITISH COLUMBIA / ACCESS Newswire / January 6, 2026 / lobe sciences ltd. (CSE:LOBE)(OTCQB:LOBEF)(FWB:LOBE.F) ("Lobe" or the "Company"), a biopharmaceutical company advancing programs in diseases with unmet medical needs, today reported audited financial results for the fiscal year... Keep Reading...
Numinus Wellness Provides Corporate Update

Numinus Wellness Provides Corporate Update

Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, is providing a corporate update.Change of auditorsOn October 10,... Keep Reading...

Interactive Chart

Latest Press Releases

Related News